Skip To Main Content
Michael T. Yin on Muck Rack

Michael T. Yin

As seen in: Nature, PLOS, MDPI, Taylor & Francis Online, BioRxiv, The Lancet, Positively Aware
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Michael T.

Contact Michael T., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Bispecific 10E8.4/iMab broadly neutralizing antibody in people with or without HIV-1: a partially randomized phase 1 trial

|
By Deborah Theodore, Bryan Mayer, Charlotte-Paige Rolle, Edwin DeJesus, Margaret E Ackerman, Michael S. Seaman, Joshua Weiner, Hiroshi Mohri, Yaoxing Huang, Brett Gray, Jennifer Chang Verified, Monica Gerber, Jian Yu, Yang Luo, Neal N. Padte, Michael T. Yin, Burc Barin, Steven Palmer, Jorge Benitez, Chanc Orzell, David Ho, Ollivier Hyrien, Magdalena E. Sobieszczyk, Rusty Greene, Ariana Pazmino, Carlie Dorr, Meredith McNairy, James DiRenzo
| Nature Verified
Abstract Broadly neutralizing antibodies (bnAbs) are a promising tool for HIV prevention and treatment. Here we conducted a first-in-human, phase 1 trial of the bispecific 10E8.4/iMab antibody, which consists of a 10E8.4 arm binding the HIV-1 envelope glycoprotein membrane-proximal external region and an ibalizumab (iMab) arm binding the human CD4 molecule. 10E8.4/iMab was administered intravenously (IV) or subcutaneously (SC).
Open in Who Shared Issue with article?

A First-in-Class Dual Degrader of Bcl-2/Bcl-xL Reverses HIV Latency and Minimizes Ex Vivo Reservoirs from Patients

|
By Lin-Chun Chang, Michael T. Yin, Gregory M Laird, Kristen D Ritter
| MDPI
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Open in Who Shared Issue with article?

Navigating menopause with HIV

|
By Sara Bares, Sara E. Looby, Michael T. Yin
| Positively Aware Verified
Menopause is a natural process that occurs when a woman’s ovaries stop producing eggs as the production of the female hormones (estrogen and progesterone) decline. Menopause can also occur if a woman’s ovaries are removed or injured. Natural menopause is comprised of different stages. Perimenopause (also known as the menopausal transition) typically begins when a woman is in her mid-40s. During perimenopause, menstrual periods become irregular and eventually begin to taper off.
Open in Who Shared Issue with article?
See all 9 articles